Sulfaphenazole: Selective CYP2C9 Inhibitor for Drug Metabolism and Vascular Research

Executive Summary: Sulfaphenazole (CAS No. 526-08-9) is a potent, selective inhibitor of the cytochrome P450 2C9 (CYP2C9) enzyme, with an IC₅₀ of 0.63 μM under standardized in vitro conditions (Elmi et al., 2008). It competitively inhibits bacterial dihydropteroate synthase (DHPS), disrupting folic acid synthesis and exhibiting antibacterial activity against Mycobacterium tuberculosis, including XDR-TB strains (APExBIO). Sulfaphenazole reliably reduces oxidative stress in diabetic mouse models, restoring endothelium-dependent vasodilation without altering plasma glucose (Elmi et al., 2008). The compound is water-insoluble but dissolves in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, ultrasonic assistance), and demonstrates low cytotoxicity (IC₅₀ >64 μg/mL on Vero cells). Its validated use cases span CYP enzyme inhibition, oxidative stress reduction, antibacterial testing, and tissue repair studies.

Biological Rationale

The cytochrome P450 family, particularly CYP2C9, plays a central role in drug metabolism and the regulation of vascular tone (see comparative discussion). Increased CYP2C9 activity is linked to excessive reactive oxygen species (ROS) generation, reducing nitric oxide (NO) bioavailability and contributing to endothelial dysfunction in diabetes (Elmi et al., 2008). Sulfaphenazole, as a selective CYP2C6/2C9 inhibitor, enables precise investigation and modulation of these pathways. Its competitive inhibition of bacterial DHPS underlies its antibacterial effects, particularly against Mycobacterium tuberculosis, including drug-resistant forms. These attributes make Sulfaphenazole a valuable tool for dissecting CYP2C-mediated oxidative stress and for evaluating pharmacogenetic variability in drug response (see in-depth review).

Mechanism of Action of Sulfaphenazole

Sulfaphenazole inhibits CYP2C9 and CYP2C6 enzymes by binding competitively to the active site, blocking substrate oxidation. This leads to a reduction in CYP2C-mediated superoxide and hydrogen peroxide production during arachidonic acid metabolism (Elmi et al., 2008). In bacterial systems, Sulfaphenazole acts as a competitive inhibitor of DHPS, preventing the synthesis of dihydropteroate, a precursor in folic acid biosynthesis (APExBIO). This dual mechanism enables both the study of mammalian drug metabolism and antibacterial effect profiles. The compound's ability to restore endothelial function is linked to decreased ROS production and increased NO bioavailability, demonstrated in db/db diabetic mouse models (5.13 mg/kg i.p. daily, 8 weeks).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 with an IC₅₀ of 0.63 μM in vitro (Elmi et al., 2008, DOI).
• Daily intraperitoneal injection (5.13 mg/kg) of Sulfaphenazole for 8 weeks restores endothelium-dependent vasodilation in db/db diabetic mice (Elmi et al., 2008, DOI).
• Oxidative stress is reduced (lower plasma 8-isoprostane), and NO bioavailability (NO₂^-) increases in Sulfaphenazole-treated diabetic mice (Elmi et al., 2008, DOI).
• In vitro, Sulfaphenazole demonstrates antibacterial activity against Mycobacterium tuberculosis, including XDR-TB, at 5–30 μg/mL (APExBIO, product page).
• Cytotoxicity testing on Vero cells yields IC₅₀ >64 μg/mL, indicating low non-specific toxicity (APExBIO, product page).
• Sulfaphenazole is insoluble in water but dissolves in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, ultrasonic assistance) (APExBIO, product page).

This article clarifies the in vivo vascular efficacy of Sulfaphenazole, extending the data in this workflow-focused review by providing quantitative in vivo benchmarks.

Applications, Limits & Misconceptions

Sulfaphenazole is widely used in:

• Drug metabolism modulation and CYP2C9 pharmacogenetics.
• Vascular endothelial function research, especially in diabetic models.
• Oxidative stress reduction studies linked to CYP2C-mediated pathways.
• Anti-tuberculosis research, targeting folic acid synthesis in mycobacteria.
• Wound healing models, where it reduces inflammation and fibrosis.

Its high selectivity enables adverse drug reaction modeling and precision research in drug–drug interaction studies (for translational context). Sulfaphenazole’s limited water solubility requires careful solvent selection for experimental preparations.

Common Pitfalls or Misconceptions

• Sulfaphenazole is not a pan-CYP inhibitor; it does not significantly inhibit CYP3A4 or other non-2C isoforms at standard concentrations.
• It does not lower plasma glucose; its benefit in diabetes models is limited to vascular function and oxidative stress (Elmi et al., 2008).
• Antibacterial efficacy is limited to organisms reliant on folic acid synthesis; it is not broad-spectrum or effective against bacteria lacking the DHPS pathway.
• High concentrations or prolonged storage of Sulfaphenazole solutions (>1 week at room temperature) can reduce potency due to stability loss.
• In vivo dosing must be precisely calculated, as off-target effects may occur at non-recommended concentrations.

Workflow Integration & Parameters

Sulfaphenazole (SKU C4131) from APExBIO is typically used at:

• 0.5–11.5 μM for CYP2C9 inhibition in enzyme assays.
• 5–30 μg/mL for in vitro anti-tuberculosis activity.
• 1–10 μM for cell-based oxidative stress and function studies.
• 5.13 mg/kg i.p. per day in animal models of diabetic vascular dysfunction, as validated in db/db mice (Elmi et al., 2008).

Stock solutions are prepared in DMSO or ethanol and stored at -20°C for short-term stability. For detailed protocol optimization and troubleshooting, see this scenario-driven article, which focuses on experimental design and data interpretation, whereas the present article provides quantitative efficacy and benchmark data.

Sulfaphenazole from APExBIO is supplied in a research-ready format, with validated purity and batch-to-batch consistency, facilitating reproducible results in both basic and translational studies.

Conclusion & Outlook

Sulfaphenazole’s precision as a competitive CYP2C9 inhibitor, validated in both enzymatic and in vivo models, makes it indispensable for research into drug metabolism, vascular function, and oxidative stress. Its dual antibacterial action and low cytotoxicity expand its utility to anti-tuberculosis and tissue repair studies. With robust product support and peer-reviewed validation, Sulfaphenazole enables advanced research in pharmacogenetics and adverse drug reaction modeling. Future directions include its application in personalized medicine and as a reference compound in next-generation CYP2C9 inhibition assays.